News
AGIO
31.52
-0.47%
-0.15
Agios Pharma (AGIO) Receives a Buy from Piper Sandler
TipRanks · 4d ago
Weekly Report: what happened at AGIO last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at AGIO last week (0408-0412)?
Weekly Report · 04/15 09:03
Agios Pharmaceuticals (NASDAQ:AGIO) adds US$58m to market cap in the past 7 days, though investors from five years ago are still down 50%
The Agios Pharmaceuticals, Inc. Share price has gained 27% in the last three months. The company saw its revenue shrink by 51% per year over the last five years. The share price is up 3.6% over the past three months, but over the longer term the returns have been dismal. It is a loss making company with falling revenue. Agios pharmaceuticals is showing 2 warning signs in our analysis of the company.
Simply Wall St · 04/10 10:03
Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticals
Benzinga · 04/09 12:27
Analysts Have Conflicting Sentiments on These Healthcare Companies: Alnylam Pharma (ALNY), Gilead Sciences (GILD) and Agios Pharma (AGIO)
TipRanks · 04/09 02:50
Weekly Report: what happened at AGIO last week (0401-0405)?
Weekly Report · 04/08 09:03
Weekly Report: what happened at AGIO last week (0325-0329)?
Weekly Report · 04/01 09:03
Weekly Report: what happened at AGIO last week (0318-0322)?
Weekly Report · 03/25 09:03
Weekly Report: what happened at AGIO last week (0311-0315)?
Weekly Report · 03/18 09:03
Weekly Report: what happened at AGIO last week (0304-0308)?
Weekly Report · 03/11 09:03
Agios Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 03/06 04:21
Weekly Report: what happened at AGIO last week (0226-0301)?
Weekly Report · 03/04 09:03
Weekly Report: what happened at AGIO last week (0219-0223)?
Weekly Report · 02/26 09:03
Agios Pharmaceuticals Price Target Cut to $30.00/Share From $31.00 by JP Morgan
Dow Jones · 02/23 17:44
Agios Pharmaceuticals Is Maintained at Neutral by JP Morgan
Dow Jones · 02/23 17:44
Agios Pharmaceuticals Up Nearly 11%, on Pace for Largest Percent Increase Since September 2022 -- Data Talk
Agios Pharmaceuticals, Inc. Is currently at $29.74, up $2.94 or 10.97%. Company is on pace for largest percent increase since Sept. 8, 2022. Up four of the past six days, up 31.48% month-to-date.
Dow Jones · 02/22 19:10
Weekly Report: what happened at AGIO last week (0212-0216)?
Weekly Report · 02/19 09:03
Optimistic Outlook for Agios Pharma: A Buy Rating Amidst Pyrukynd Sales Miss and Promising ENERGIZE-T Trial Prospects
Despite a recent sales miss for Pyrukynd, Agios Pharma has a positive outlook. Management remains confident in the upcoming ENERGIZE-T trial results. Leerink Partners has maintained their Buy rating on AGIO stock. The company is a biopharmaceutical company developing treatments for rare genetic diseases.
TipRanks · 02/19 04:46
Bearish: Analysts Just Cut Their Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenue and EPS estimates
Agios Pharmaceuticals, Inc. Shares are up 5.4% in the past 7 days after analysts downgraded their forecasts for this year. Revenue and earnings per share forecasts were both revised downwards for the company. The most recent consensus is for revenues of US$43m in 2024. The company's losses per share is expected to increase to US$5.80 per share. Despite the downgrade, the price target for the stock remains unchanged.
Simply Wall St · 02/17 12:16
More
Webull provides a variety of real-time AGIO stock news. You can receive the latest news about Agios Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About AGIO
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.